http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sung Chul Choi ),( Beom Jin Kim ),( Poong Lyul Rhee ),( Dong Kyung Chang ),( Hee Jung Son ),( Jae J. Kim ),( Jong Chul Rhee ),( Soon Im Kim ),( Young Sil Han ),( Ki Hyeon Sim ),( Seok Nam Park ) 대한소화기기능성질환·운동학회 2011 Gut and Liver Vol.5 No.1
Background/Aims: Although controversial, probiotics and dietary fiber are commonly used for patients with irritable bowel syndrome (IBS). We evaluated the effects of multistrain probiotics on the symptoms of IBS to determine whether the addition of dietary fi ber had an additive effect on constipation-predominant IBS. Methods: A total of 142 participants who met the Rome III criteria were recruited and randomized into a control group or a test group. Participants in the control group received multistrain probiotic fermented milk with Streptococcus thermophilus, Lactobacillus acidophilus and Bifi dobacterium infantis; the participants in the test group received the same probiotic fermented milk mixed with dietary fi ber such as sea tangle extracts, radish extracts and glasswort extracts. The patients were treated for four weeks. Results: Most of the symptoms of IBS, with the exception of fl atulence, stool consistency, and frequency of defecation, signifi cantly improved in both groups. In the analysis of IBS subtypes, especially constipation-predominant IBS, the frequency and duration of defecation and straining at stool were improved more in the test group than in the control group. Conclusions: Dietary fiber had additive benefits for the symptoms of constipation, especially in constipationpredominant IBS. (Gut Liver 2011;5:22-28)
Role of vitamin D-binding protein in isocyanate-induced occupational asthma
Sung-Ho Kim,최길순,Young-Hee Nam,김주희,허규영,김승현,박상면,박해심 생화학분자생물학회 2012 Experimental and molecular medicine Vol.44 No.5
The development of a serological marker for early diagnosis of isocyanate-induced occupational asthma (isocyanate-OA) may improve clinical outcome. Our previous proteomic study found that expression of vitamin D-binding protein (VDBP) was upregulated in the patients with isocyanate-OA. In the present study, we evaluated the clinical relevance of VDBP as a serological marker in screening for isocyanate-OA among exposed workers and its role in the pathogenesis of isocyanate-OA. Three study groups including 61 patients with isocyanate-OA (group I), 180 asymptomatic exposed controls (AECs, group II), 58 unexposed healthy controls (NCs, group III) were enrolled in this study. The baseline serum VDBP level was significantly higher in group I compared with groups II and III. The sensitivity and specificity for predicting the phenotype of isocyanate-OA with VDBP were 69% and 81%, respectively. The group I subjects with high VDBP (≥ 311 μg/ml) had significantly lower PC20 methacholine levels than did subjects with low VDBP. The in vitro studies showed that TDI suppressed the uptake of VDBP into RLE-6TN cells, which was mediated by the downregulation of megalin, an endocytic receptor of the 25-hydroxycholecalciferol-VDBP complex. Furthermore,toluene diisocyanate (TDI) increased VEGF production and secretion from this epithelial cells by suppression of 1,25-dihydroxycholecalciferol [1,25(OH)2D3]production. The findings of this study suggest that the serum VDBP level may be used as a serological marker for the detection of isocyanate-OA among workers exposed to isocyanate. The TDI-induced VEGF production/secretion was reversed by 1,25(OH)2D3 treatment,which may provide a potential therapeutic strategy for patients with isocyanate-OA.
Low Speed Control of Induction Machines with inertia identification
Nam-Joo Kim,Hee-Sung Moon,Dong-Myung Lee,Dong-Seok Hyun 전력전자학회 1995 ICPE(ISPE)논문집 Vol.1995 No.10
This paper presents a control method of induction machine in a low speed range with the instantaneous speed observer and inertia identification. When the low resolution incremental-type encoder is used for the speed detection, we get only the average speed between the interval of the encoder pulses and it makes usually speed controller unstable at the very low speed range. This paper, therefore, proposes a low speed control method using the low precision shaft encoder with speed observer implementing the disturbance torque observer. Furthermore, to improve the performance of the speed controller, we will perform the inertia iden tification algorithm using th e estimated inertia acquired by the periodic test signal. We will show that this proposed method is superior to the conventional method by simulation and experimental results.
Nam-Su Lee,Jae-Ho Byun,Sang-Byung Bae,Chan-Kyu Kim,Kyu-Taeg Lee,박성규,Jong-Ho Won,Dae-Sik Hong,Hee-Sook Park 대한암학회 2004 Cancer Research and Treatment Vol.36 No.3
PURPOSE: The prognosis of patients with advanced non-small-cell lung cancer (NSCLC) is extremely poor. Many prospective randomized trials on patients with advanced NSCLC suggested systemic chemotherapy improves both the survival and quality of life. A phase II trial was conducted to evaluate the efficacy and safety profile of the combination chemotherapy of gemcitabine and cisplatin in advanced NSCLC. MATERIALS AND METHODS: Forty-four patients with locally advanced or metastatic NSCLC were enrolled. The patients received a cisplatin, 75 mg/m2, infusion over 30 minutes on days 1, followed by a gemcitabine, 1,250 mg/m2, infusion over 30 minutes on days 1 and 8 every 3 weeks. RESULTS: The median age of the patients was 64 years (range: 27~75). Forty-one patients were assessable for response and toxicity analyses. The overall response rate was 53.6%, but with no complete remissions. The median time to progression was 5.6 months (range: 1~15.4). The median survival was 14.2 months (95% confidence interval (CI), 13.8~22.5). A total of 179 cycles were administered, with a median of 4 cycles of chemotherapy, ranging from 2 to 9 cycles. The most common hematological toxicities were NCI grades 3/4 neutropenia (24%) and thrombocytopenia (7.8%). The most common non-hematological toxicity was fatigue (42.4%). There were no life-threatening toxicity or treatment related mortalities. The median duration of follow up was 9.4 months, ranging from 1.6 to 30.3 months. CONCLUSION: In this trial, the combination of gemcitabine and cisplatin showed significant activity, with acceptable and manageable toxicities as a first-line regimen for patients with advanced NSCLC. (Cancer Res Treat. 2004;36:173-177)